NRX Pharmaceuticals (NRXP) Total Liabilities (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported Total Liabilities for 10 consecutive years, with $34.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities fell 15.14% year-over-year to $34.3 million in Q2 2026; TTM through Jun 2026 was $34.3 million, a 15.14% decrease from a year earlier, with the FY2025 full-year figure at $28.9 million, up 7.51% from the prior year.
• Total Liabilities was $34.3 million for Q2 2026 at NRX Pharmaceuticals, up from $25.7 million in the prior quarter.
• Over five years, Total Liabilities peaked at $40.8 million in Q3 2025 and troughed at $7.1 million in Q2 2022.
• A 5-year average of $23.6 million and a median of $23.0 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities plunged 87.86% in 2022 and jumped 219.4% in 2023, its largest moves.
• Over 5 years, Total Liabilities stood at $18.4 million in 2022, then gained by 3.48% to $19.0 million in 2023, then soared by 41.09% to $26.9 million in 2024, then climbed by 7.51% to $28.9 million in 2025, then advanced by 18.82% to $34.3 million in 2026.
• The last three Total Liabilities figures came in at $34.3 million (Q2 2026), $25.7 million (Q1 2026), and $28.9 million (Q4 2025), per Business Quant data.